Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
21 hedge funds and large institutions have $31.8M invested in Argos Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.98% less ownership
Funds ownership: 23.38% → 22.4% (-0.98%)
16% less funds holding
Funds holding: 25 → 21 (-4)
22% less capital invested
Capital invested by funds: $41M → $31.8M (-$9.2M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
+$64.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.2K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.1K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$6.55K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$479 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$263K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$228K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$195K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$94K |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
-$67.1K |
ARGS Hedge Fund Activity: Q2 2015 in Review
21 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q2 2015, worth a combined $31.8M — down 22% from $41M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ARGS and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Stoneridge Investment Partners, adding an estimated $64.2K. The largest seller was HighTower Advisors, exiting entirely with an estimated $263K sold.
- 21 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q2 2015, down from 25 in Q1 2015.
- Funds reported $31.8M of Argos Therapeutics, Inc. stock for Q2 2015, down 22% quarter-over-quarter.
- 1 fund opened new Argos Therapeutics, Inc. positions in Q2 2015 and 5 closed out, a net change of -4 holders.
- The largest Argos Therapeutics, Inc. buyer in Q2 2015 was Stoneridge Investment Partners, an estimated $64.2K added.
- The largest Argos Therapeutics, Inc. seller in Q2 2015 was HighTower Advisors, an estimated $263K sold.
Based on aggregated 13F filings for Q2 2015.